TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07751250: Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function

Sponsor: Arcus Biosciences, Inc. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$3,454,128

Rescue Site Savings

+$2,280,176

Unlock Full NCT07751250 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07751250 Rescue Dossier →